Skip to main content
 

Our Actos News

It's a sad and all-too common story, particularly in the pharmaceutical industry. They know there is a risk or potentially dangerous side effect to one of their profitable products and they don't…

The Actos MDL (2299) is in full force. The Initial Status Conference will be this week on Thursday, March 22nd.  Judge Rebecca Doherty of the United States District Court, Western District of…

Type 1 (childhood onset) and Type 2 (adult onset) diabetes are really two different diseases with completely different causes. There is some commonality…

Exanatide is an alternative treatment for type 2 diabetes that has been around for awhile. Unlike Actos and Avandia – which work by trying to…

This news probably have the makers of Actos, Avandia and other diabetic drugs pitching a fit.

 

A recent report now indicates that the market for diabetic drugs is poised to grow by almost 120% over the next four years – something that has Big Pharma doing the Happy Dance.  Not…

Bryan Helm. who works for the Cape May-Lewes Ferry in Ocean City New Jersey, has his Type-2 diabetes under tight control - the best outcome possible for such patients.  First diagnosed over a…

According to a recent article in the New England Journal of Medicine, two of the four drugs most likely to result in hospitalization among the elderly are those used to treat diabetes.…

The risk factors for Type 2 diabetes are well known, but worth reviewing: primarily, these factors are obesity in combination with a sedentary lifestyle, and genetics.

 

The…

At the end of September, I reported on a "new" drug from Actos maker Takeda pharmaceutical, which is currently marketed outside the U.S. as Nesina.

Subscribe to Actos News
Customize This